Found 169 matches for
The world’s largest randomised clinical trial of potential coronavirus treatments is well underway in the UK as part of the race to find a treatment.
Inaugural Webinar of CCOUC 10th Anniversary International Webinar Series on Health Emergency and Disaster Risk Management cum IRDR Global Research Agenda Pre-Session: Latest frontier and application of Health-EDRM within the scope of COVID-19
14 April 2021
Collaborating Centre for Oxford University and CUHK for Disaster and Medical Humanitarian Response (CCOUC) was established by the joint effort of Oxford University and The Chinese University of Hong Kong as a non-profit research centre to carry out research, training and community knowledge transfer in the area of disaster and medical humanitarian response in Greater China and the Asia-Pacific Region a decade ago on 19 April 2011.
6 April 2021
The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.
24 March 2021
Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival. From having no known effective drugs when the pandemic first erupted, patients are now offered treatments that have been robustly proven to reduce death and improve other outcomes, such as the length of hospital stay and the need for mechanical ventilation.
22 March 2021
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.
10 March 2021
Professor Cecilia Lindgren has been appointed as the new Director of the University of Oxford’s Big Data Institute. Professor Lindgren will take up post on 1 April 2021. She succeeds Professor Gil McVean who was the founding director of the BDI, and Interim Director, Professor Martin Landray.
5 March 2021
NDM's Professor Sarah Gilbert has been awarded the Royal Society for Arts’ (RSA) Albert Medal for her work on the Oxford vaccine. Professor Gilbert is Professor of Vaccinology and the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.
18 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join and recruited to RECOVERY International. NDM's Peter Horby, Professor of Emerging Infectious Diseases and Global Health, and Joint Chief Investigator for the trial, said ‘The RECOVERY trial has been an enormous success, enrolling over 36,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies".
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease
15 February 2021
Exscientia, the leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).
12 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) has demonstrated that an anti-inflammatory treatment, tocilizumab, reduces the risk of death when given to hospitalised patients with severe COVID-19.
10 February 2021
Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found.
29 January 2021
The CRUK Oxford Centre is pleased to announce the appointment of Professor Tim Elliot as its new co-Director. Tim has recently joined the Nuffield Department of Medicine and Oriel College as the Kidani Professor of Immuno-Oncology. He re-joins the Oxford community from Southampton University, having previously completed his undergraduate degree in Biochemistry at Balliol and subsequently holding a Professorial post at the Weatherall Institute for Molecular Medicine.
Lateral flow devices detect most infectious COVID-19 cases and could allow a safer relaxation of the current lockdown
22 January 2021
Researchers from NDM's Big Data Institute working with Public Health England and NHS Test and Trace, have used Test and Trace data to find out why some individuals pass COVID-19 on to their contacts more easily than others, and if lateral flow tests are sufficient in detecting those who are most infectious
19 January 2021
A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).
31 December 2020
Congratulations to Sir Dave Stuart, FRS FMedSci, NDM’s Professor of Structural Biology, knighted for services to medical research and the scientific community.
30 December 2020
The Nuffield Department of Medicine welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
16 December 2020
Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand.
14 December 2020
RECOVERY reports absence of a benefit from Azithromycin. The latest result from the NDM/NDPH RECOVERY trial shows the widely administered administration of a broad-spectrum antibiotic makes no difference to the routine outcome in hospitalised COVID19 disease. Results on other therapies are likely to follow in the coming weeks.
11 December 2020
Data from the National COVID-19 Infection Survey, done in partnership between the University of Oxford, the Office of National Statistics, Public Health England, University of Manchester and the Wellcome Trust, has revealed detailed characteristics of England’s coronavirus pandemic, including which factors have contributed most to case numbers over different phases and the prevalence of asymptomatic infections.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
9 December 2020
Today, the University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%. The new study published in the Lancet is the first peer-reviewed publication of phase 3 data from studies of a vaccine against the coronavirus.
23 November 2020
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.